OncoMatch/Clinical Trials/NCT07175480
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
Is NCT07175480 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Intermittent PD-1/PD-L1 ICI + VEGFR-TKI for renal cell carcinoma (rcc).
Treatment: Intermittent PD-1/PD-L1 ICI + VEGFR-TKI — This phase 2 trial aims to test the feasibility and efficiency of PET/CT-directed treatment interruption strategy in metastatic renal cell carcinoma patients with IMDC favorable/intermediate risk who achieve complete (CMR) or partial metabolic response (PMR) after ≥12 months of first-line PD-1/PD-L1 Immune checkpoint inhibitor (ICI)+ VEGFR-tyrosine kinase inhibitor (TKI) therapy. It helps figure out whether PET/CT can safely direct treatment pause as well as explores a new individualized treatment option based on metabolic imaging for RCC patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy — first-line
Patient must receive≥12 months of first line treatment with the combination of PD-1/PD-L1 ICI and VEGFR-TKI, and have not experienced a toxicity that prevents them from continuing on therapy.
Must have received: anti-PD-L1 therapy — first-line
Patient must receive≥12 months of first line treatment with the combination of PD-1/PD-L1 ICI and VEGFR-TKI, and have not experienced a toxicity that prevents them from continuing on therapy.
Must have received: VEGFR inhibitor — first-line
Patient must receive≥12 months of first line treatment with the combination of PD-1/PD-L1 ICI and VEGFR-TKI, and have not experienced a toxicity that prevents them from continuing on therapy.
Cannot have received: systemic therapy
Prior systemic therapy for advanced RCC
Lab requirements
Blood counts
anc ≥ 1.5 × 10³/μl (≥ 1.5 gi/l); platelet count ≥ 100 × 10³/μl (≥ 100 gi/l); hemoglobin ≥ 9 g/dl (≥ 90 g/l)
Kidney function
serum creatinine ≤ 2.0 × upper limit of normal or calculated creatinine clearance ≥ 30 ml/min using the cockroft-gault formula
Liver function
alt and ast < 2.5 × upper limit of normal. total bilirubin ≤ 1.5 × the upper limit of normal (≤ 3 mg/dl [≤ 51.3 μmol/l] if gilbert's syndrome)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07175480 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages